跳至主要内容
临床试验/NL-OMON48479
NL-OMON48479已完成不适用

A randomized, double-blind, placebo-controlled single and multiple ascending dose study of the safety, tolerability and pharmacokinetics of oral doses of SAR443122 in healthy adult subjects. - SAD and MAD of SAR443122

Sanofi-aventis0 个研究点目标入组 97 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
97

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • healthy male or female subjects
  • 18 - 55 years
  • 50 - 100 kg
  • BMI 18.0 - 30.0 kg/m2

排除标准

  • Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of
  • participation in another drug study within 90 days before the start of this
  • study or being a blood donor within 60 days from the start of the study. In
  • case of donating more than 1.5 liters of blood in the 10 months prior the start
  • of this study.

研究者

相似试验